B+
Bull case
20%
Probability
Target price
$18.00
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
KZIA
Kazia TherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The completed offering provides approximately $40 million in upfront gross proceeds for development, while trial execution and later efficacy data could strengthen the paxalisib case. The additional roughly $80 million described in the offering depends on warrant exercise and is not secured cash.
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta -10.1.
What can break
The FDA's stated need for additional glioblastoma evidence leaves the registrational path unresolved. [#SEC-20F-2025] Kazia annual filing
Momentum
7
Value
49
Sentiment
72
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $9.00 · Bull $18.00 · Bear $4.00Analysis 2026-10-02; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-02 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-23
Investment thesis
As of 2026-10-23
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $31.57
Why
Momentum7 · Δ7d -0.6
Value49 · Δ7d 0.0
Sentiment72 · Δ7d -10.1
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta -10.1.
Contradictions & invalidation
- • The FDA's stated need for additional glioblastoma evidence leaves the registrational path unresolved. [#SEC-20F-2025] Kazia annual filing
- • The HR+/HER2- and colorectal-cancer expansion cases rely substantially on preclinical evidence; enrollment delays, safety findings or weak patient outcomes could undermine them. SEC-filed HR+/HER2- release SEC-filed colorectal-cancer release
- • Clinical benefit remains unproven across the new indications.
Catalyst clock
2026-12-31
First patient in HR+/HER2- breast-cancer expansion
Lead driver: Sentiment · See AI snapshot
Momentum
7
8% active weight
Current posture
7d trendSoftening
Δ7d
-0.6
Δ21d
-2.1
Value
49
47% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
0.0
Sentiment
72
45% active weight
Current posture
7d trendSoftening
Δ7d
-10.1
Δ21d
+13.5
Why this grade
Composite grade B. Momentum 6.9 / Value 49.3 / Sentiment 72.3
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-02. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$9.00
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
B-
Bear case
35%
Probability
Target price
$4.00
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-23
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$89.24M
Beta
1.79
Shares Out
11.43M
P/E (TTM) · Derived
-2.1
P/S (TTM)
802.17
P/FCF (TTM) · Derived
-1.30
Rev YoY
-96.3%
EPS YoY
+96.8%
Gross Margin
+64.0%
Op Margin
-21258.8%
Net Debt
-$2.59M
Current Ratio
2.87
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data